Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist
The market has bet on the explosive demand for GLP-1 drugs and has begun to position these companies as 'growth stocks.' Lilly has surpassed electric vehicle manufacturer Tesla in market capitalization to enter the top 10 US companies, and Novo also briefly jumped to the position of Europe's largest company
A doping/sport note (because it comes up in searches) WADAs prohibited list explicitly references growth hormone fragments, including AOD-9604 / hGH 176191
While doing so will inevitably increase a laboratorys costs, such increase would be a small price to pay, given that the alternative is the wrongful charging of athletes based on unreliable laboratory reports issued pursuant to the flawed Section 4 Substances regime
US$ 20.31
US$ 26.24
US$ 26.46
